Aplastic anemia (AA) and hypoplastic myelodysplastic syndrome are paradigms of
autoimmune hematopoietic failure (AHF). Myelodysplastic syndrome and acute myeloid …

Venetoclax, a small-molecule B-cell lymphoma 2 (BCL-2) inhibitor, selectively eradicates
leukemic stem cells (LSCs). While venetoclax has revolutionized the treatment of acute …

In AML with NPM1 mutation causing cytoplasmic dislocation of NPM1, treatments with Menin
inhibitor (MI) and standard AML chemotherapy yield complete remissions. However, the …

Acute myeloid leukemia (AML) is a disease characterized by abnormal cell proliferation in
the bone marrow and is the most common quickly progressive leukemia in adults …

Acute myeloid leukemia (AML) is a genetically extremely heterogeneous disease. Drug
resistance after induction therapy is a very frequent event resulting in poor medium survival …

Simple Summary Therapeutic advances in acute myeloid leukemia (AML) are dependent on
identifying and targeting the molecular aberrations that drive disease. The European …

BACKGROUND Myelodysplastic syndrome (MDS) is caused by malignant proliferation and
ineffective hematopoiesis. Oncogenic somatic mutations and increased apoptosis …

Abstract Treatment paradigms for acute myeloid leukemia (AML) have evolved at a rapid
pace in recent years. The combination of venetoclax with a hypomethylating agent …

BACKGROUND Accumulating evidence demonstrates that autoimmune hematopoietic
failure and myeloid neoplasms have an intrinsic relationship with regard to clonal …

BACKGROUND Myelodysplastic syndrome (MDS) is a hematological neoplasm, and an
increase in myeloblasts is representative of leukemic hematopoiesis in advanced MDS. Low …